bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table from Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
Authors: Konopleva Marina , Thirman Michael J. , Pratz Keith W. , Garcia Jacqueline S. , Recher Christian , Pullarkat Vinod , Kantarjian Hagop M. , DiNardo Courtney D. , Dail Monique , Duan Yinghui , Chyla Brenda , Potluri Jalaja , Miller Catherine L. , Wei Andrew H.
Published: April 2023

Supplementary Table from Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
Supplementary Table from Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial
Authors: Zhang Zhanjie , Wu Bian , Peng Gang , Xiao Guixiang , Huang Jing , Ding Qian , Yang Chengzhang , Xiong Xingao , Ma Hui , Shi Liangliang , Yang Jinsong , Hong Xiaohua , Wei Jielin , Qin You , Wan Chao , Zhong Yi , Zhou Yan , Zhao Xueyan , Leng Yangming , Zhang Tao , Wu Gang , Yao Min , Zhang Xiaomeng , Yang Kunyu
Published: April 2023

Supplementary Table from Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial
Supplementary Data from Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC
Authors: Jung Hyun Ae , Lim Jinyeong , Choi Yoon-La , Lee Se-Hoon , Joung Je-Gun , Jeon Yeong Jeong , Choi Jae Won , Shin Sumin , Cho Jong Ho , Kim Hong Kwan , Choi Yong Soo , Zo Jae Ill , Shim Young Mog , Park Sehhoon , Sun Jong-Mu , Ahn Jin Seok , Ahn Myung-Ju , Han Joungho , Park Woong-Yang , Kim Jhingook , Park Keunchil
Published: April 2023

Supplementary Data from Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC
Supplementary Data from Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Authors: Tolaney Sara M. , Toi Masakazu , Neven Patrick , Sohn Joohyuk , Grischke Eva-Maria , Llombart-Cussac Antonio , Soliman Hatem , Wang Hong , Wijayawardana Sameera , Jansen Valerie M. , Litchfield Lacey M. , Sledge George W.
Published: April 2023

Supplementary Data from Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Authors: van Putten Erik H.P. , Kleijn Anne , van Beusechem Victor W. , Noske David , Lamers Cor H.J. , de Goede Anna L. , Idema Sander , Hoefnagel Daphna , Kloezeman Jenneke J. , Fueyo Juan , Lang Frederick F. , Teunissen Charlotte E. , Vernhout René M. , Bakker Cathy , Gerritsen Winald , Curiel David T. , Vulto Arnold , Lamfers Martine L.M. , Dirven Clemens M.F.
Published: April 2023

Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Authors: Zhu Mojun , Chen Chunhua , Foster Nathan R. , Hartley Christopher , Mounajjed Taofic , Salomao Marcela A. , Fruth Briant F. , Beamer Staci E. , Kim Yohan , Harrington Susan M. , Pitot Henry C. , Sanhueza Cristobal T. , Feng Yening , Herrmann Joerg , McWilliams Robert R. , Lucien Fabrice , Huang Bing Q. , Ma Wen Wee , Bekaii-Saab Tanios S. , Dong Haidong , Wigle Dennis , Ahn Daniel H. , Hallemeier Chris L. , Blackmon Shanda , Yoon Harry H.
Published: April 2023

Supplementary Figure from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Supplementary Figure from Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection
Authors: Le Xiuning , Gleber-Netto Frederico O. , Rubin M. Laura , Qing Yun , Du Robyn , Kies Merrill , Blumenschein George , Lu Charles , Johnson Faye M. , Bell Diana , Lewis Jeff , Zhang Jiexin , Feng Lei , Wilson Kaye , Marcelo-Lewis Kathrina , Wang Jing , Ginsberg Lawrence , Gillison Maura , Lee J. Jack , Meric-Berstam Funda , Mills Gordon B. , Myers Jeffrey N. , Pickering Curtis R.
Published: April 2023

Supplementary Figure from Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection
Supplementary Figure from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Authors: Vesely Clare , Wong Yien Ning Sophia , Childs Alexa , Akarca Ayse U. , Dhami Pawan , Vaikkinen Heli , Conde Lucia , Herrero Javier , Ogunbiyi Olagunju , Gander Amir , Luong Tu Vinh , Thirlwell Chrissie , Caplin Martyn , Toumpanakis Christos , Peggs Karl , Quezada Sergio A. , Marafioti Teresa , Meyer Tim
Published: April 2023

Supplementary Figure from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Supplementary Data from Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Authors: Jung Hyun Ae , Park Sehhoon , Choi Yoon-La , Lee Se-Hoon , Ahn Jin Seok , Ahn Myung-Ju , Sun Jong-Mu
Published: April 2023

Supplementary Data from Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Supplementary Table from Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
Authors: Llovet Josep M. , Singal Amit G. , Villanueva Augusto , Finn Richard S. , Kudo Masatoshi , Galle Peter R. , Ikeda Masafumi , Callies Sophie , McGrath Louise M. , Wang Chunxiao , Abada Paolo , Widau Ryan C. , Gonzalez-Gugel Elena , Zhu Andrew X.
Published: April 2023

Supplementary Table from Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
Supplementary Table from Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer
Authors: Xu Junfen , Fang Yifeng , Chen Kelie , Li Sen , Tang Sangsang , Ren Yan , Cen Yixuan , Fei Weidong , Zhang Bo , Shen Yuanming , Lu Weiguo
Published: April 2023

Supplementary Table from Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer
Supplementary Figure from ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
Authors: Johnson Melissa , Dudek Arkadiusz Z. , Sukari Ammar , Call Justin , Kunk Paul R. , Lewis Karl , Gainor Justin F. , Sarantopoulos John , Lee Patrice , Golden Adele , Harney Allison , Rothenberg S. Michael , Zhang Yuanyuan , Goldman Jonathan W.
Published: April 2023

Supplementary Figure from ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
Supplementary Figure from Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade
Authors: Triozzi Pierre L. , Stirling Elizabeth R. , Song Qianqian , Westwood Brian , Kooshki Mitra , Forbes M. Elizabeth , Holbrook Beth C. , Cook Katherine L. , Alexander-Miller Martha A. , Miller Lance D. , Zhang Wei , Soto-Pantoja David R.
Published: April 2023

Supplementary Figure from Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade
Supplementary Figure from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Authors: Lee Chung-Han , Motzer Robert , Emamekhoo Hamid , Matrana Marc , Percent Ivor , Hsieh James J. , Hussain Arif , Vaishampayan Ulka , Liu Sandy , McCune Steven , Patel Vijay , Shaheen Montaser , Bendell Johanna , Fan Alice C. , Gartrell Benjamin A. , Goodman Oscar B. , Nikolinakos Petros G. , Kalebasty Arash Rezazadeh , Zakharia Yousef , Zhang Zhentao , Parmar Hema , Akella Lalith , Orford Keith , Tannir Nizar M.
Published: April 2023

Supplementary Figure from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Supplementary Figure from Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Chung Christine H. , Li Jiannong , Steuer Conor E. , Bhateja Priyanka , Johnson Matthew , Masannat Jude , Poole Maria I. , Song Feifei , Hernandez-Prera Juan C. , Molina Helen , Wenig Bruce M. , Kumar Sunil , Kuperwasser Charlotte , Stephens Philip J. , Farinhas Joaquim M. , Shin Dong M. , Kish Julie A. , Muzaffar Jameel , Kirtane Kedar , Rocco James W. , Schell Michael J. , Saba Nabil F. , Bonomi Marcelo
Published: April 2023

Supplementary Figure from Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Figure from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Authors: Nayak Lakshmi , Standifer Nathan , Dietrich Jorg , Clarke Jennifer L. , Dunn Gavin P. , Lim Michael , Cloughesy Timothy , Gan Hui K. , Flagg Elizabeth , George Elizabeth , Gaffey Sarah , Hayden Julia , Holcroft Christina , Wen Patrick Y. , Macri Mary , Park Andrew J. , Ricciardi Toni , Ryan Aileen , Schwarzenberger Paul , Venhaus Ralph , Reyes Melissa de los , Durham Nicholas M. , Creasy Todd , Huang Raymond Y. , Kaley Thomas , Reardon David A.
Published: April 2023

Supplementary Figure from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Supplementary Table from Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth
Authors: Madhavan Krishna , Balakrishnan Ilango , Lakshmanachetty Senthilnath , Pierce Angela , Sanford Bridget , Fosmire Susan , Elajaili Hanan B. , Walker Faye , Wang Dong , Nozik Eva S. , Mitra Siddhartha S. , Dahl Nathan A. , Vibhakar Rajeev , Venkataraman Sujatha
Published: April 2023

Supplementary Table from Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth
Supplementary Figure from Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth
Authors: Madhavan Krishna , Balakrishnan Ilango , Lakshmanachetty Senthilnath , Pierce Angela , Sanford Bridget , Fosmire Susan , Elajaili Hanan B. , Walker Faye , Wang Dong , Nozik Eva S. , Mitra Siddhartha S. , Dahl Nathan A. , Vibhakar Rajeev , Venkataraman Sujatha
Published: April 2023

Supplementary Figure from Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth
Supplementary Table from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Authors: Davar Diwakar , Zappasodi Roberta , Wang Hong , Naik Girish S. , Sato Takami , Bauer Todd , Bajor David , Rixe Olivier , Newman Walter , Qi Jingjing , Holland Aliya , Wong Phillip , Sifferlen Lianna , Piper Diane , Sirard Cynthia A. , Merghoub Taha , Wolchok Jedd D. , Luke Jason J.
Published: April 2023

Supplementary Table from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Supplementary Figure from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Authors: Davar Diwakar , Zappasodi Roberta , Wang Hong , Naik Girish S. , Sato Takami , Bauer Todd , Bajor David , Rixe Olivier , Newman Walter , Qi Jingjing , Holland Aliya , Wong Phillip , Sifferlen Lianna , Piper Diane , Sirard Cynthia A. , Merghoub Taha , Wolchok Jedd D. , Luke Jason J.
Published: April 2023

Supplementary Figure from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
Authors: Blenman Kim R.M. , Marczyk Michal , Karn Thomas , Qing Tao , Li Xiaotong , Gunasekharan Vignesh , Yaghoobi Vesal , Bai Yalai , Ibrahim Eiman Y. , Park Tristen , Silber Andrea , Wolf Denise M. , Reisenbichler Emily , Denkert Carsten , Sinn Bruno V. , Rozenblit Mariya , Foldi Julia , Rimm David L. , Loibl Sibylle , Pusztai Lajos
Published: April 2023

Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma
Authors: Lodrini Marco , Graef Josefine , Thole-Kliesch Theresa M. , Astrahantseff Kathy , Sprüssel Annika , Grimaldi Maddalena , Peitz Constantin , Linke Rasmus B. , Hollander Jan F. , Lankes Erwin , Künkele Annette , Oevermann Lena , Schwabe Georg , Fuchs Jörg , Szymansky Annabell , Schulte Johannes H. , Hundsdörfer Patrick , Eckert Cornelia , Amthauer Holger , Eggert Angelika , Deubzer Hedwig E.
Published: April 2023

Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma
Supplementary Table from RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition
Authors: Hunihan Lisa , Zhao Dejian , Lazowski Heather , Li Man , Qian Yuping , Abriola Laura , Surovtseva Yulia V. , Muthusamy Viswanathan , Tanoue Lynn T. , Rothberg Bonnie E. Gould , Schalper Kurt A. , Herbst Roy S. , Wilson Frederick H.
Published: April 2023

Supplementary Table from RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition
Supplementary Figure from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
Authors: Serritella Anthony V. , Shevrin Daniel , Heath Elisabeth I. , Wade James L. , Martinez Elia , Anderson Amanda , Schonhoft Joseph , Chu Yen-Lin , Karrison Theodore , Stadler Walter M. , Szmulewitz Russell Z.
Published: April 2023

Supplementary Figure from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
Supplementary Data from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study
Authors: Nathenson Michael J. , Hu Junxiao , Ratan Ravin , Somaiah Neeta , Hsu Robert , DeMaria Peter J. , Catoe Heath W. , Pang Angela , Subhawong Ty K. , Amini Behrang , Sweet Kevin , Feister Katharina , Malik Karan , Jagannathan Jyothi , Braschi-Amirfarzan Marta , Sheren Jamie , Caldas Yupanqui , Moreno Tellez Cristiam , Rosenberg Andrew E. , Lazar Alexander J. , Maki Robert G. , Benedetto Pasquale , Cohen Jonathan , Trent Jonathan C. , Ravi Vinod , Patel Shreyaskumar , Wilky Breelyn A.
Published: April 2023

Supplementary Data from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study
Supplementary Figure from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab
Authors: Innocenti Federico , Yazdani Akram , Rashid Naim , Qu Xueping , Ou Fang-Shu , Van Buren Scott , Bertagnolli Monica M. , Kabbarah Omar , Blanke Charles David , Venook Alan P. , Lenz Heinz-Josef , Vincent Benjamin G.
Published: April 2023

Supplementary Figure from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab
Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
Authors: Draaisma Kaspar , Tesileanu C. Mircea S. , de Heer Iris , Klein Martin , Smits Marion , Reijneveld Jaap C. , Clement Paul M. , de Vos Filip Y.F. , Wick Antje , Mulholland Paul J. , Taphoorn Martin J.B. , Weller Michael , Chinot Olivier L. , Kros Johan M. , Verschuere Tina , Coens Corneel , Golfinopoulos Vassilis , Gorlia Thierry , Idbaih Ahmed , Robe Pierre A. , van den Bent Martin J. , French Pim J.
Published: April 2023

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
Supplementary Data from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab
Authors: Innocenti Federico , Yazdani Akram , Rashid Naim , Qu Xueping , Ou Fang-Shu , Van Buren Scott , Bertagnolli Monica M. , Kabbarah Omar , Blanke Charles David , Venook Alan P. , Lenz Heinz-Josef , Vincent Benjamin G.
Published: April 2023

Supplementary Data from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Authors: Sowalsky Adam G. , Figueiredo Ines , Lis Rosina T. , Coleman Ilsa , Gurel Bora , Bogdan Denisa , Yuan Wei , Russo Joshua W. , Bright John R. , Whitlock Nichelle C. , Trostel Shana Y. , Ku Anson T. , Patel Radhika A. , True Lawrence D. , Welti Jonathan , Jimenez-Vacas Juan M. , Rodrigues Daniel Nava , Riisnaes Ruth , Neeb Antje , Sprenger Cynthia T. , Swain Amanda , Wilkinson Scott , Karzai Fatima , Dahut William L. , Balk Steven P. , Corey Eva , Nelson Peter S. , Haffner Michael C. , Plymate Stephen R. , de Bono Johann S. , Sharp Adam
Published: April 2023

Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Authors: Voss Martin H. , Azad Arun A. , Hansen Aaron R. , Gray Jhanelle E. , Welsh Sarah J. , Song Xuyang , Kuziora Michael , Meinecke Lina , Blando Jorge , Achour Ikbel , Wang Yi , Walcott Farzana L. , Oosting Sjoukje F.
Published: April 2023

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Supplementary Data from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Authors: Voss Martin H. , Azad Arun A. , Hansen Aaron R. , Gray Jhanelle E. , Welsh Sarah J. , Song Xuyang , Kuziora Michael , Meinecke Lina , Blando Jorge , Achour Ikbel , Wang Yi , Walcott Farzana L. , Oosting Sjoukje F.
Published: April 2023

Supplementary Data from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Supplementary Figure from HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma
Authors: Sasame Jo , Ikegaya Naoki , Kawazu Masahito , Natsumeda Manabu , Hayashi Takahiro , Isoda Masataka , Satomi Kaishi , Tomiyama Arata , Oshima Akito , Honma Hirokuni , Miyake Yohei , Takabayashi Katsuhiro , Nakamura Taishi , Ueno Toshihide , Matsushita Yuko , Iwashita Hiromichi , Kanemaru Yu , Murata Hidetoshi , Ryo Akihide , Terashima Keita , Yamanaka Shoji , Fujii Yukihiko , Mano Hiroyuki , Komori Takashi , Ichimura Koichi , Cahill Daniel P. , Wakimoto Hiroaki , Yamamoto Tetsuya , Tateishi Kensuke
Published: April 2023

Supplementary Figure from HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma
Supplementary Figure from Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma
Authors: Yoshida Kosuke , Yokoi Akira , Yamamoto Tomofumi , Hayashi Yusuke , Nakayama Jun , Yokoi Tsuyoshi , Yoshida Hiroshi , Kato Tomoyasu , Kajiyama Hiroaki , Yamamoto Yusuke
Published: April 2023

Supplementary Figure from Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma
Supplementary Figure from Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
Authors: Coleman Ilsa M. , DeSarkar Navonil , Morrissey Colm , Xin Li , Roudier Martine P. , Sayar Erolcan , Li Dapei , Corey Eva , Haffner Michael C. , Nelson Peter S.
Published: April 2023

Supplementary Figure from Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure from DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome
Authors: Guidry Kayla , Vasudevaraja Varshini , Labbe Kristen , Mohamed Hussein , Serrano Jonathan , Guidry Brett W. , DeLorenzo Michael , Zhang Hua , Deng Jiehui , Sahu Soumyadip , Almonte Christina , Moreira Andre L. , Tsirigos Aristotelis , Papagiannakopoulos Thales , Pass Harvey , Snuderl Matija , Wong Kwok-Kin
Published: April 2023

Supplementary Figure from DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome
Supplementary Figure from Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade
Authors: Wang Wei , Lozar Taja , Golfinos Athena E. , Lee Denis , Gronski Ellery , Ward-Shaw Ella , Hayes Mitchell , Bruce Justine Y. , Kimple Randall J. , Hu Rong , Harari Paul M. , Xu Jin , Keske Aysenur , Sondel Paul M. , Fitzpatrick Megan B. , Dinh Huy Q. , Lambert Paul F.
Published: April 2023

Supplementary Figure from Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade
Supplementary Data from DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome
Authors: Guidry Kayla , Vasudevaraja Varshini , Labbe Kristen , Mohamed Hussein , Serrano Jonathan , Guidry Brett W. , DeLorenzo Michael , Zhang Hua , Deng Jiehui , Sahu Soumyadip , Almonte Christina , Moreira Andre L. , Tsirigos Aristotelis , Papagiannakopoulos Thales , Pass Harvey , Snuderl Matija , Wong Kwok-Kin
Published: April 2023

Supplementary Data from DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome
Supplementary Data from Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade
Authors: Wang Wei , Lozar Taja , Golfinos Athena E. , Lee Denis , Gronski Ellery , Ward-Shaw Ella , Hayes Mitchell , Bruce Justine Y. , Kimple Randall J. , Hu Rong , Harari Paul M. , Xu Jin , Keske Aysenur , Sondel Paul M. , Fitzpatrick Megan B. , Dinh Huy Q. , Lambert Paul F.
Published: April 2023

Supplementary Data from Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade
Supplementary Table from Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
Authors: Zizzari Ilaria Grazia , Di Filippo Alessandra , Botticelli Andrea , Strigari Lidia , Pernazza Angelina , Rullo Emma , Pignataro Maria Gemma , Ugolini Alessio , Scirocchi Fabio , Di Pietro Francesca Romana , Rossi Ernesto , Gelibter Alain , Schinzari Giovanni , D'Amati Giulia , Rughetti Aurelia , Marchetti Paolo , Nuti Marianna , Napoletano Chiara
Published: April 2023

Supplementary Table from Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
Supplementary Figure from Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
Authors: Zizzari Ilaria Grazia , Di Filippo Alessandra , Botticelli Andrea , Strigari Lidia , Pernazza Angelina , Rullo Emma , Pignataro Maria Gemma , Ugolini Alessio , Scirocchi Fabio , Di Pietro Francesca Romana , Rossi Ernesto , Gelibter Alain , Schinzari Giovanni , D'Amati Giulia , Rughetti Aurelia , Marchetti Paolo , Nuti Marianna , Napoletano Chiara
Published: April 2023

Supplementary Figure from Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
Supplementary Data from Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements
Authors: Vougiouklakis Theodore , Zhu Kelsey , Vasudevaraja Varshini , Serrano Jonathan , Shen Guomiao , Linn Rebecca L. , Feng Xiaojun , Chiang Sarah , Barroeta Julieta E. , Thomas Kristen M. , Schwartz Lauren E. , Shukla Pratibha S. , Malpica Anais , Oliva Esther , Cotzia Paolo , DeLair Deborah F. , Snuderl Matija , Jour George
Published: April 2023

Supplementary Data from Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements
Supplementary Figure from BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
Authors: Mehnert Janice M. , Mitchell Tara C. , Huang Alexander C. , Aleman Tomas S. , Kim Benjamin J. , Schuchter Lynn M. , Linette Gerald P. , Karakousis Giorgos C. , Mitnick Sheryl , Giles Lydia , Carberry Mary , Frey Noelle , Kossenkov Andrew , Groisberg Roman , Hernandez-Aya Leonel F. , Ansstas George , Silk Ann W. , Chandra Sunandana , Sosman Jeffrey A. , Gimotty Phyllis A. , Mick Rosemarie , Amaravadi Ravi K.
Published: April 2023

Supplementary Figure from BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
Authors: Demetri George D. , De Braud Filippo , Drilon Alexander , Siena Salvatore , Patel Manish R. , Cho Byoung Chul , Liu Stephen V. , Ahn Myung-Ju , Chiu Chao-Hua , Lin Jessica J. , Goto Koichi , Lee Jeeyun , Bazhenova Lyudmila , John Thomas , Fakih Marwan , Chawla Sant P. , Dziadziuszko Rafal , Seto Takashi , Heinzmann Sebastian , Pitcher Bethany , Chen David , Wilson Timothy R. , Rolfo Christian
Published: April 2023

Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
Supplementary Data from Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients
Authors: Wang Jun , Kunzke Thomas , Prade Verena M. , Shen Jian , Buck Achim , Feuchtinger Annette , Haffner Ivonne , Luber Birgit , Liu Drolaiz H.W. , Langer Rupert , Lordick Florian , Sun Na , Walch Axel
Published: April 2023

Supplementary Data from Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients
Supplementary Figure from Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Authors: Mack Philip C. , Miao Jieling , Redman Mary W. , Moon James , Goldberg Sarah B. , Herbst Roy S. , Melnick Mary Ann , Walther Zenta , Hirsch Fred R. , Politi Katerina , Kelly Karen , Gandara David R.
Published: April 2023

Supplementary Figure from Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Supplementary Data from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
Authors: Demetri George D. , De Braud Filippo , Drilon Alexander , Siena Salvatore , Patel Manish R. , Cho Byoung Chul , Liu Stephen V. , Ahn Myung-Ju , Chiu Chao-Hua , Lin Jessica J. , Goto Koichi , Lee Jeeyun , Bazhenova Lyudmila , John Thomas , Fakih Marwan , Chawla Sant P. , Dziadziuszko Rafal , Seto Takashi , Heinzmann Sebastian , Pitcher Bethany , Chen David , Wilson Timothy R. , Rolfo Christian
Published: April 2023

Supplementary Data from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Authors: Zhu Andrew X. , Dayyani Farshid , Yen Chia-Jui , Ren Zhenggang , Bai Yuxian , Meng Zhiqiang , Pan Hongming , Dillon Paul , Mhatre Shivani K. , Gaillard Vincent E. , Hernandez Sairy , Kelley Robin Kate , Sangro Bruno
Published: April 2023

Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Supplementary Data from Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Authors: Mack Philip C. , Miao Jieling , Redman Mary W. , Moon James , Goldberg Sarah B. , Herbst Roy S. , Melnick Mary Ann , Walther Zenta , Hirsch Fred R. , Politi Katerina , Kelly Karen , Gandara David R.
Published: April 2023

Supplementary Data from Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Supplementary Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Authors: Stephens Deborah M. , Huang Ying , Ruppert Amy S. , Walker Janek S. , Canfield Daniel , Cempre Casey B. , Fu Qiang , Baker Sharyn , Hu Boyu , Shah Harsh , Vadeboncoeur Renee , Rogers Kerry A. , Bhat Seema , Jaglowski Samantha M. , Lockman Hank , Lapalombella Rosa , Byrd John C. , Woyach Jennifer A.
Published: April 2023

Supplementary Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Supplementary Figure from Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Authors: Goldman Jonathan W. , Piha-Paul Sarina A. , Curti Brendan , Pedersen Katrina S. , Bauer Todd M. , Groenland Stefanie L. , Carvajal Richard D. , Chhaya Vaishali , Kirby Gray , McGlinchey Kelly , Hammond Scott A. , Streicher Katie , Townsley Danielle M. , Chae Young Kwang , Voortman Jens , Marabelle Aurelien , Powderly John
Published: April 2023

Supplementary Figure from Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Supplementary Data from Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial
Authors: Shuen Timothy Wai Ho , Alunni-Fabbroni Marianna , Öcal Elif , Malfertheiner Peter , Wildgruber Moritz , Schinner Regina , Pech Maciej , Benckert Julia , Sangro Bruno , Kuhl Christiane , Gasbarrini Antonio , Chow Pierce Kah Hoe , Toh Han Chong , Ricke Jens
Published: April 2023

Supplementary Data from Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial
Supplementary Table from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Authors: Hoes Louisa R. , van Berge Henegouwen Jade M. , van der Wijngaart Hanneke , Zeverijn Laurien J. , van der Velden Daphne L. , van de Haar Joris , Roepman Paul , de Leng Wendy J. , Jansen Anne M.L. , van Werkhoven Erik , van der Noort Vincent , Huitema Alwin D.R. , Gort Eelke H. , de Groot Jan Willem B. , Kerver Emile D. , de Groot Derk Jan , Erdkamp Frans , Beerepoot Laurens V. , Hendriks Mathijs P. , Smit Egbert F. , van der Graaf Winette T.A. , van Herpen Carla M.L. , Labots Mariette , Hoeben Ann , Morreau Hans , Lolkema Martijn P. , Cuppen Edwin , Gelderblom Hans , Verheul Henk M.W. , Voest Emile E.
Published: April 2023

Supplementary Table from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Supplementary Figure from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Authors: Hoes Louisa R. , van Berge Henegouwen Jade M. , van der Wijngaart Hanneke , Zeverijn Laurien J. , van der Velden Daphne L. , van de Haar Joris , Roepman Paul , de Leng Wendy J. , Jansen Anne M.L. , van Werkhoven Erik , van der Noort Vincent , Huitema Alwin D.R. , Gort Eelke H. , de Groot Jan Willem B. , Kerver Emile D. , de Groot Derk Jan , Erdkamp Frans , Beerepoot Laurens V. , Hendriks Mathijs P. , Smit Egbert F. , van der Graaf Winette T.A. , van Herpen Carla M.L. , Labots Mariette , Hoeben Ann , Morreau Hans , Lolkema Martijn P. , Cuppen Edwin , Gelderblom Hans , Verheul Henk M.W. , Voest Emile E.
Published: April 2023

Supplementary Figure from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Supplementary Table from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Authors: Zhou Qing , Gampenrieder Simon P. , Frantal Sophie , Rinnerthaler Gabriel , Singer Christian F. , Egle Daniel , Pfeiler Georg , Bartsch Rupert , Wette Viktor , Pichler Angelika , Petru Edgar , Dubsky Peter C. , Bago-Horvath Zsuzsanna , Fesl Christian , Rudas Margaretha , Ståhlberg Anders , Graf Ricarda , Weber Sabrina , Dandachi Nadia , Filipits Martin , Gnant Michael , Balic Marija , Heitzer Ellen
Published: April 2023

Supplementary Table from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Authors: Zhou Qing , Gampenrieder Simon P. , Frantal Sophie , Rinnerthaler Gabriel , Singer Christian F. , Egle Daniel , Pfeiler Georg , Bartsch Rupert , Wette Viktor , Pichler Angelika , Petru Edgar , Dubsky Peter C. , Bago-Horvath Zsuzsanna , Fesl Christian , Rudas Margaretha , Ståhlberg Anders , Graf Ricarda , Weber Sabrina , Dandachi Nadia , Filipits Martin , Gnant Michael , Balic Marija , Heitzer Ellen
Published: April 2023

Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models
Authors: Li Fuyang , Bondra Kathryn M. , Ghilu Samson , Studebaker Adam , Liu Qianqian , Michalek Joel E. , Kogiso Mari , Li Xiao-Nan , Kalapurakal John A. , James C. David , Burma Sandeep , Kurmasheva Raushan T. , Houghton Peter J.
Published: April 2023

Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models
Supplementary Data from Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells
Authors: Corradi Giulia , Bassani Barbara , Simonetti Giorgia , Sangaletti Sabina , Vadakekolathu Jayakumar , Fontana Maria Chiara , Pazzaglia Martina , Gulino Alessandro , Tripodo Claudio , Cristiano Gianluca , Bandini Lorenza , Ottaviani Emanuela , Ocadlikova Darina , Piccioli Milena , Martinelli Giovanni , Colombo Mario Paolo , Rutella Sergio , Cavo Michele , Ciciarello Marilena , Curti Antonio
Published: April 2023

Supplementary Data from Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells
Supplementary Figure from Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Authors: Nowakowski Grzegorz S. , Yoon Dok Hyun , Peters Anthea , Mondello Patrizia , Joffe Erel , Fleury Isabelle , Greil Richard , Ku Matthew , Marks Reinhard , Kim Kibum , Zinzani Pier Luigi , Trotman Judith , Huang Dan , Waltl Eva E. , Winderlich Mark , Kurukulasuriya Nuwan C. , Ambarkhane Sumeet , Hess Georg , Salles Gilles
Published: April 2023

Supplementary Figure from Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Supplementary Figure from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Authors: Bundred Nigel , Porta Nuria , Brunt Adrian Murray , Cramer Angela , Hanby Andrew , Shaaban Abeer M. , Rakha Emad A. , Armstrong Anne , Cutress Ramsey I. , Dodwell David , Emson Marie A. , Evans Abigail , Hartup Sue M. , Horgan Kieran , Miller Sarah E. , McIntosh Stuart A. , Morden James P. , Naik Jay , Narayanan Sankaran , Ooi Jane , Skene Anthony I. , Cameron David A. , Bliss Judith M.
Published: April 2023

Supplementary Figure from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Supplementary Figure from PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma
Authors: An Jihyun , Oh Minyoung , Kim Seog-Young , Oh Yoo-Jin , Oh Bora , Oh Ji-Hye , Kim Wonkyung , Jung Jin Hwa , Kim Ha Il , Kim Jae-Seung , Sung Chang Ohk , Shim Ju Hyun
Published: April 2023

Supplementary Figure from PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma
Supplementary Data from PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma
Authors: An Jihyun , Oh Minyoung , Kim Seog-Young , Oh Yoo-Jin , Oh Bora , Oh Ji-Hye , Kim Wonkyung , Jung Jin Hwa , Kim Ha Il , Kim Jae-Seung , Sung Chang Ohk , Shim Ju Hyun
Published: April 2023

Supplementary Data from PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma
Supplementary Figure from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
Authors: Xu-Monette Zijun Y. , Wei Li , Fang Xiaosheng , Au Qingyan , Nunns Harry , Nagy Máté , Tzankov Alexandar , Zhu Feng , Visco Carlo , Bhagat Govind , Dybkaer Karen , Chiu April , Tam Wayne , Zu Youli , Hsi Eric D. , Hagemeister Fredrick B. , Sun Xiaoping , Han Xin , Go Heounjeong , Ponzoni Maurilio , Ferreri Andrés J.M. , Møller Michael B. , Parsons Benjamin M. , van Krieken J. Han , Piris Miguel A. , Winter Jane N. , Li Yong , Xu Bing , Albitar Maher , You Hua , Young Ken H.
Published: April 2023

Supplementary Figure from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
Supplementary Figure from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Authors: Inaba Hiroto , van Oosterwijk Jolieke G. , Panetta John C. , Li Lie , Buelow Daelynn R. , Blachly James S. , Shurtleff Sheila , Pui Ching-Hon , Ribeiro Raul C. , Rubnitz Jeffrey E. , Pounds Stanley , Baker Sharyn D.
Published: April 2023

Supplementary Figure from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Supplementary Figure from Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis
Authors: Penel Nicolas , Bonvalot Sylvie , Bimbai André-Michel , Meurgey Alexandra , Le Loarer François , Salas Sébastien , Piperno-Neumann Sophie , Chevreau Christine , Boudou-Rouquette Pascaline , Dubray-Longeras Pascale , Kurtz Jean-Emmanuel , Guillemet Cécile , Bompas Emmanuelle , Italiano Antoine , Le Cesne Axel , Orbach Daniel , Thery Julien , Le Deley Marie-Cécile , Blay Jean-Yves , Mir Olivier
Published: April 2023

Supplementary Figure from Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis
Supplementary Figure from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Authors: Guerrero Camila , Puig Noemi , Cedena Maria-Teresa , Goicoechea Ibai , Perez Cristina , Garcés Juan-José , Botta Cirino , Calasanz Maria-Jose , Gutierrez Norma C. , Martin-Ramos Maria-Luisa , Oriol Albert , Rios Rafael , Hernandez Miguel-Teodoro , Martinez-Martinez Rafael , Bargay Joan , de Arriba Felipe , Palomera Luis , Gonzalez-Rodriguez Ana Pilar , Mosquera-Orgueira Adrian , Gonzalez-Perez Marta-Sonia , Martinez-Lopez Joaquin , Lahuerta Juan-José , Rosiñol Laura , Blade Joan , Mateos Maria-Victoria , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Figure from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Supplementary Figure from Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Authors: Sabari Joshua K. , Velcheti Vamsidhar , Shimizu Kazuhide , Strickland Matthew R. , Heist Rebecca S. , Singh Mohini , Nayyar Naema , Giobbie-Hurder Anita , Digumarthy Subba R. , Gainor Justin F. , Rajan Anant P. , Nieblas-Bedolla Edwin , Burns Aaron C. , Hallin Jill , Olson Peter , Christensen James G. , Kurz Sylvia C. , Brastianos Priscilla K. , Wakimoto Hiroaki
Published: April 2023

Supplementary Figure from Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Supplementary Data from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Authors: Guerrero Camila , Puig Noemi , Cedena Maria-Teresa , Goicoechea Ibai , Perez Cristina , Garcés Juan-José , Botta Cirino , Calasanz Maria-Jose , Gutierrez Norma C. , Martin-Ramos Maria-Luisa , Oriol Albert , Rios Rafael , Hernandez Miguel-Teodoro , Martinez-Martinez Rafael , Bargay Joan , de Arriba Felipe , Palomera Luis , Gonzalez-Rodriguez Ana Pilar , Mosquera-Orgueira Adrian , Gonzalez-Perez Marta-Sonia , Martinez-Lopez Joaquin , Lahuerta Juan-José , Rosiñol Laura , Blade Joan , Mateos Maria-Victoria , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Data from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Supplementary Table from Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Authors: Madanat-Harjuoja Laura M. , Klega Kelly , Lu Yao , Shulman David S. , Thorner Aaron R. , Nag Anwesha , Tap William D. , Reinke Denise K. , Diller Lisa , Ballman Karla V. , George Suzanne , Crompton Brian D.
Published: April 2023

Supplementary Table from Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Supplementary Figure from Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Authors: Madanat-Harjuoja Laura M. , Klega Kelly , Lu Yao , Shulman David S. , Thorner Aaron R. , Nag Anwesha , Tap William D. , Reinke Denise K. , Diller Lisa , Ballman Karla V. , George Suzanne , Crompton Brian D.
Published: April 2023

Supplementary Figure from Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Supplementary Figure from Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma
Authors: Aragon-Sanabria Virginia , Aditya Anusha , Zhang Li , Chen Feng , Yoo Barney , Cao Tianye , Madajewski Brian , Lee Rachel , Turker Melik Z. , Ma Kai , Monette Sebastien , Chen Peiming , Wu Jing , Ruan Shutian , Overholtzer Michael , Zanzonico Pat , Rudin Charles M. , Brennan Cameron , Wiesner Ulrich , Bradbury Michelle S.
Published: April 2023

Supplementary Figure from Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma
Supplementary Figure from Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
Authors: Kim Chang Gon , Sim Nam Suk , Kim Jeong Eun , Yun Kum-Hee , Lee Young Han , Kim Seung Hyun , Baek Wooyeol , Han Yoon Dae , Kim Sang Kyum , Kim Jee Hung , Koh Yoon Woo , Jung Inkyung , Shin Su-Jin , Rha Sun Young , Ahn Jin-Hee , Kim Hyo Song
Published: April 2023

Supplementary Figure from Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
Supplementary Figure from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Authors: Hemming Matthew L. , Bhola Patrick , Loycano Michael A. , Anderson Justin A. , Taddei Madeleine L. , Doyle Leona A. , Lavrova Elizaveta , Andersen Jessica L. , Klega Kelly S. , Benson Morgan R. , Crompton Brian D. , Raut Chandrajit P. , George Suzanne , Letai Anthony , Demetri George D. , Sicinska Ewa
Published: April 2023

Supplementary Figure from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Supplementary Data from Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Authors: Cristofanilli Massimo , Rugo Hope S. , Im Seock-Ah , Slamon Dennis J. , Harbeck Nadia , Bondarenko Igor , Masuda Norikazu , Colleoni Marco , DeMichele Angela , Loi Sherene , Iwata Hiroji , O'Leary Ben , André Fabrice , Loibl Sibylle , Bananis Eustratios , Liu Yuan , Huang Xin , Kim Sindy , Lechuga Frean Maria Jose , Turner Nicholas C.
Published: April 2023

Supplementary Data from Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study